Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Allogene Therapeutics (ALLO) Net Margin (2021 - 2024)

Allogene Therapeutics' Net Margin history spans 4 years, with the latest figure at 291231.82% for Q1 2024.

  • For Q1 2024, Net Margin rose 3907485.0% year-over-year to 291231.82%; the TTM value through Dec 2024 reached 1151031.82%, down 87926803.0%, while the annual FY2024 figure was 1170863.64%, 82637416.0% down from the prior year.
  • Net Margin for Q1 2024 was 291231.82% at Allogene Therapeutics, up from 375447.62% in the prior quarter.
  • Across five years, Net Margin topped out at 2.5% in Q4 2021 and bottomed at 2411525.0% in Q4 2022.
  • The 4-year median for Net Margin is 205107.69% (2022), against an average of 370881.15%.
  • The largest annual shift saw Net Margin plummeted -241152750bps in 2022 before it skyrocketed 203607738bps in 2023.
  • A 4-year view of Net Margin shows it stood at 2.5% in 2021, then tumbled by -96373200bps to 2411525.0% in 2022, then skyrocketed by 84bps to 375447.62% in 2023, then increased by 22bps to 291231.82% in 2024.
  • Per Business Quant, the three most recent readings for ALLO's Net Margin are 291231.82% (Q1 2024), 375447.62% (Q4 2023), and 132023.26% (Q3 2023).